Skip to main content
. 2017 Aug 10;8(45):78633–78641. doi: 10.18632/oncotarget.20203

Table 4. Multivariate analyses of the correlation between SNPs and treatment efficacy at 3 months after radiotherapy.

SNPs Genotypes Primary tumor efficacy1 (n=128) Lymph node efficacy1 (n=108)
CR2 Non-CR2 OR 95%CI P CR2 Non-CR2 OR 95%CI P
XRCC1 rs25489 GG:GA 84/28/6 7/3/0 1.351 0.243-7.502 0.731 71/22/4 8/3/0 1.150 0.225-5.881 0.866
GG:AA - - - - - -
GG:(GA+AA) 1.032 0.196-5.425 0.970 1.052 0.208-5.310 0.951
(GG+GA):AA - - - - - -
OGG1 rs1052133 CC:CG 38/58/22 6/4/0 0.535 0.122-2.334 0.405 35/44/18 2/5/4 1.838 0.296-11.401 0.514
CC:GG - - - 3.795 0.555-25.975 0.174
CC:(CG+GG) 0.335 0.079-1.427 0.139 2.446 0.455-13.154 0.297
(CC+CG):GG - - - 2.617 0.588-11.656 0.207
APE(X)1 rs1130409 TT:TG 40/65/13 5/4/1 0.480 0.096-2.407 0.372 32/55/10 5/4/2 0.574 0.118-2.802 0.493
TT:GG 0.479 0.037-6.166 0.572 1.116 0.141-8.859 0.917
TT:(TG+GG) 0.479 0.106-2.166 0.339 0.702 0.171-2.875 0.623
(TT+TG):GG 0.666 0.057-7.756 0.745 1.375 0.184-10.300 0.756

1 Adjusted for age, gender, drinking, smoking, family history, BMI, TNM stage and clinical stage, treatment and EBV-DNA.

2 Wild homozygote / heterozygote / mutant homozygote.

SNPs, single nucleotide polymorphisms; CR, complete remission; OR, odds ratio; 95%CI, 95% confidence interval.

P values < 0.05 are shown in bold.